{"id":"b3f28d87-f892-56a5-b7d6-68b5732de4fb","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-human-combined-nad","predicate":"increases_in_recorded_comparison","statement":"The 2024 multicomponent trial reported a 26.5% increase from baseline at day 28 in its main whole-blood NAD assay.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"c4bc8c74-e1b2-5db9-a523-2ae2bdccec7b","mechanism_event_label":"The 2024 multicomponent trial reported a 26.5% increase from baseline at day 28 in its main whole-blood NAD assay.","subject":{"id":"3b9d39d2-dcd2-5453-b25f-2ec41fc3f10b","slug":"nuchido-time-plus-2024","display_name":"Nuchido TIME+ multicomponent preparation in the 2024 trial","entity_type_key":"chemical_species"},"object":{"id":"339eae26-3ea0-5b58-afb2-7632be461509","slug":"whole-blood-nad-nadh-assay","display_name":"Whole-blood NAD+ plus NADH assay signal","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"c4bc8c74-e1b2-5db9-a523-2ae2bdccec7b","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-human-combined-nad-event","event_type":"experimental_observation","label":"The 2024 multicomponent trial reported a 26.5% increase from baseline at day 28 in its main whole-blood NAD assay.","description":"### api-human-combined-nad\n\nThe 2024 multicomponent trial reported a 26.5% increase from baseline at day 28 in its main whole-blood NAD assay.\nThe Methods describe total NAD+ plus NADH, despite NAD+ terminology elsewhere. Main P=0.007. This is not an isolated-apigenin trial or demonstrated slowing of aging.\nModel and exposure: Randomized double-blind crossover; 26 completed, 23 in the main assay analysis.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: The use of a systems approach to increase NAD<sup>+</sup> in human participants. | 2024 | https://pubmed.ncbi.nlm.nih.gov/38302501/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC10834541/ | https://doi.org/10.1038/s41514-023-00134-0 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"3b9d39d2-dcd2-5453-b25f-2ec41fc3f10b","slug":"nuchido-time-plus-2024","display_name":"Nuchido TIME+ multicomponent preparation in the 2024 trial","entity_type_key":"chemical_species"},"role":"tested factor","stoichiometry":null,"state_label":"Nuchido TIME+ for 28 days","sequence_order":0,"notes":""},{"entity":{"id":"339eae26-3ea0-5b58-afb2-7632be461509","slug":"whole-blood-nad-nadh-assay","display_name":"Whole-blood NAD+ plus NADH assay signal","entity_type_key":"cellular_process"},"role":"measured outcome","stoichiometry":null,"state_label":"increase","sequence_order":1,"notes":""},{"entity":{"id":"4425961f-4764-56d3-9887-87e47749379b","slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"},"role":"parsley-extract constituent; amount not independently isolated","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"08c27a3f-552e-5c92-8688-321a9b64a0d6","slug":"nicotinamide","display_name":"Nicotinamide","entity_type_key":"small_molecule"},"role":"500 mg/day in preparation","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"ab091982-3acb-5a87-80fb-85dfe292c1e0","slug":"lipoic-acid","display_name":"Lipoic acid","entity_type_key":"small_molecule"},"role":"600 mg/day in preparation","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""},{"entity":{"id":"0429f0ff-c033-514b-9a4f-6f0f83268095","slug":"zinc","display_name":"Zinc","entity_type_key":"nutrient_element"},"role":"10 mg/day in preparation","stoichiometry":null,"state_label":"","sequence_order":5,"notes":""},{"entity":{"id":"da1a7137-08f2-5a36-8bb6-377fbd32e327","slug":"vitamin-c","display_name":"Vitamin C","entity_type_key":"chemical_species"},"role":"20 mg/day in preparation","stoichiometry":null,"state_label":"","sequence_order":6,"notes":""},{"entity":{"id":"22e1b8eb-f35f-5afa-be20-b0534df9f6be","slug":"egcg","display_name":"Epigallocatechin-3-gallate (EGCG)","entity_type_key":"small_molecule"},"role":"green-tea constituent","stoichiometry":null,"state_label":"","sequence_order":7,"notes":""},{"entity":{"id":"283ed24b-06a1-50aa-9281-df3bac6ce37e","slug":"nad-plus","display_name":"NAD+","entity_type_key":"small_molecule"},"role":"part of aggregate assay","stoichiometry":null,"state_label":"","sequence_order":8,"notes":""},{"entity":{"id":"9fbf2e03-16a9-5ca7-965c-0bfc07ca24da","slug":"nadh","display_name":"NADH","entity_type_key":"small_molecule"},"role":"part of aggregate assay","stoichiometry":null,"state_label":"","sequence_order":9,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"Nuchido TIME+ for 28 days\", \"comparator\": \"The active-arm baseline\", \"endpoint\": \"The 2024 multicomponent trial reported a 26.5% increase from baseline at day 28 in its main whole-blood NAD assay.\", \"effect_direction\": \"increase\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; recorded from source.","entity":null},{"dimension":"experimental_model","value_text":"Randomized double-blind crossover; 26 completed, 23 in the main assay analysis.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Recorded from source with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Apigenin collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"The 2024 multicomponent trial reported a 26.5% increase from baseline at day 28 in its main whole-blood NAD assay.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"The use of a systems approach to increase NAD<sup>+</sup> in human participants. | https://pubmed.ncbi.nlm.nih.gov/38302501/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC10834541/ | https://doi.org/10.1038/s41514-023-00134-0","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference api-human-combined-nad; The Methods describe total NAD+ plus NADH, despite NAD+ terminology elsewhere. Main P=0.007. This is not an isolated-apigenin trial or demonstrated slowing of aging.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"8b6828d2-af91-56ba-8025-812f3be2d687","evidence_kind":"source_excerpt","locator":"Lines 492-498","start_line":492,"end_line":498,"excerpt":"### api-human-combined-nad\n\nThe 2024 multicomponent trial reported a 26.5% increase from baseline at day 28 in its main whole-blood NAD assay.\nThe Methods describe total NAD+ plus NADH, despite NAD+ terminology elsewhere. Main P=0.007. This is not an isolated-apigenin trial or demonstrated slowing of aging.\nModel and exposure: Randomized double-blind crossover; 26 completed, 23 in the main assay analysis.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: The use of a systems approach to increase NAD<sup>+</sup> in human participants. | 2024 | https://pubmed.ncbi.nlm.nih.gov/38302501/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC10834541/ | https://doi.org/10.1038/s41514-023-00134-0 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","model_system":"Randomized double-blind crossover; 26 completed, 23 in the main assay analysis.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"54eac90b-add1-5f56-9036-d900307c5697","stable_key":"import-ff370329-68a3-573d-96ee-597de78a3967","title":"Apigenin: detailed mechanisms of action (reviewed 10 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed.","file_path":"","sha256":"ede6e5c6b91d66b66844f2ff667a7f8303d9ac1281f15dc09db703f7de4da942","revision_id":"b41a39a2-0197-549c-97a5-1765e6696931","review_status":"source_recorded","notes":""}}],"relations":[{"id":"f7ebf94f-9d22-57e5-83a8-2d33fd8a5b0b","relation_type":"limits_scope_of","notes":"Distinct assays and unequal sample subsets limit a single confident quantitative NAD+ claim.","source_claim_id":"3f710d5a-33ff-57ed-b69b-93bebf6ef0b3","source_claim_key":"ff370329-68a3-573d-96ee-597de78a3967:api-human-combined-lcms-null","source_statement":"The smaller LC-MS subset did not show a statistically significant NAD+ treatment effect in the same human trial.","target_claim_id":"b3f28d87-f892-56a5-b7d6-68b5732de4fb","target_claim_key":"ff370329-68a3-573d-96ee-597de78a3967:api-human-combined-nad","target_statement":"The 2024 multicomponent trial reported a 26.5% increase from baseline at day 28 in its main whole-blood NAD assay."}],"conflicts":[],"corrections":[],"research":null}